CareDX AlloMap and AlloSure post heart transplant rejection surveillance tests
Closed Pre-Solicitation Posted
Not the latest version. See the latest solicitation from .
- Solicitation number
- 36C26121Q1193
- Agency
-
Veterans Integrated Service Network 21
Veterans Health Administration, Department of Veterans Affairs
- Responses due
- Set-aside
- Total Small Business
Opportunity facts
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- PSC
- Q515 Medical- Pathology
- Place of performance
- Palo Alto, California 94304, United States
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Veterans Affairs Network Contracting Office 21 intends to award a sole source, firm fixed price contract to CareDX, Inc. for AlloMap and AlloSure post heart transplant rejection surveillance tests. These FDA approved genetic blood tests determine if a heart transplant patient has a stable transplant and is not rejecting the new heart. The proposed contract will provide these services for eligible veterans at the VA Palo Alto Health Care System. Interested parties may submit a capability statement or quotation by October 28, 2021, which will be considered before determining whether to proceed with the sole source acquisition.
This opportunity is set aside as a total small business contract. CareDX, Inc. is the potential incumbent as it currently performs these specialized tests. The solicitation will be posted on SAM.gov on or about October 8, 2021 and will include details on NAICS codes, PSC codes, and any award values or service timelines. All responsible sources are encouraged to respond by the due date if interested in providing these important medical services for veterans.
Notice text
Department of Veterans Affairs (VA) Network Contracting Office (NCO 21) intends to award a sole source, firm fixed price contract to CareDX, Inc. for AlloMap and AlloSure post heart transplant rejection surveillance tests. CareDX, Inc. performs specialized genetic blood testing on veteran patients who have undergone heart transplant surgery. The FDA approved tests determine if a heart transplant patient has a stable transplant and is not rejecting the new heart. The proposed contract will be for the VA Palo Alto Health Care System (VAPAHCS) to obtain the services for eligible veterans.
The solicitation for this action will be posted to SAM.gov, and all responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency. After consideration, the Government will determine whether to proceed with the sole source acquisition.
The solicitation will be posted on or about October 8, 2021.
Notice history
| Notice | Type | Posted |
|---|---|---|
| Sole Source CareDX AlloMap and AlloSure post heart transplant rejection surveillance tests | Solicitation | |
| This notice | Pre-Solicitation | |
| Q515--AlloMap and AlloSure post transplant rejection surveillance tests | Pre-Solicitation |
Similar open opportunities
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity